Seven Grand Managers LLC Buys Shares of 100,000 Maplight Therapeutics, Inc. $MPLT

Seven Grand Managers LLC bought a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 100,000 shares of the company’s stock, valued at approximately $1,756,000. Seven Grand Managers LLC owned about 0.22% of Maplight Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter valued at $6,835,000. Blue Owl Capital Holdings LP bought a new stake in Maplight Therapeutics during the fourth quarter valued at $5,745,000. Finally, Strs Ohio bought a new stake in Maplight Therapeutics during the fourth quarter valued at $53,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MPLT shares. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. HC Wainwright started coverage on shares of Maplight Therapeutics in a research note on Monday, May 4th. They set a “buy” rating and a $45.00 target price for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 target price for the company. Needham & Company LLC began coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price target for the company. Finally, TD Cowen began coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.89.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock opened at $29.55 on Thursday. The company has a 50-day simple moving average of $25.75 and a 200-day simple moving average of $20.29. The firm has a market capitalization of $1.26 billion and a P/E ratio of -0.72. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, sell-side analysts forecast that Maplight Therapeutics, Inc. will post -4.45 earnings per share for the current year.

Insider Buying and Selling at Maplight Therapeutics

In other news, insider Anatol Kreitzer sold 45,422 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the completion of the transaction, the insider owned 211,190 shares in the company, valued at approximately $6,263,895.40. This represents a 17.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Gillis sold 51,900 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $29.74, for a total transaction of $1,543,506.00. Following the completion of the transaction, the insider owned 199,154 shares of the company’s stock, valued at $5,922,839.96. This represents a 20.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 495,244 shares of company stock valued at $14,079,461. Corporate insiders own 3.80% of the company’s stock.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.